Treatment-resistant depression with probable OSA (MEQ)

(i) Formulation. Residual MDD (treatment-resistant trajectory) with high pretest probability of OSA (obesity, large neck, hypertension, snoring, witnessed apnoeas, unrefreshing sleep). Contributing factors: long-term temazepam, evening alcohol (worsens collapsibility and fragments sleep). Mechanisms: intermittent hypoxia and sleep fragmentation → daytime anergia, cognitive fog, mood dysregulation that mimics residual depression; longitudinal data support dose–response OSA–depression association. OSA is common in MDD/SMI clinical samples.[1][2][3]

(ii) Assessment/investigations. Structured sleep and partner history; STOP-BANG domains; ESS for sleepiness; full MSE and suicide risk; substances; medication review; BMI/BP. Urgent sleep physician referral for diagnostic testing (PSG or appropriate HSAT per AASM pathways). Medical review of hypertension. Do not delay safety advice while awaiting the study.[4][5]

(iii) Management. PAP/CPAP first-line if moderate–severe OSA confirmed; adherence support is critical; weight loss programme; stop alcohol as hypnotic; collaborative temazepam deprescribing (slow taper, warn rebound insomnia, avoid replacement with open-ended quetiapine). Optimise depression treatment in parallel (not instead of airway care). Evidence: PAP improves disease-oriented outcomes; depressive symptoms often improve with adherent CPAP.[6][8][9][10]

(iv) Driving and SAVE. Advise not to drive commercial vehicle until assessed; document counselling per jurisdiction. SAVE: CPAP did not significantly reduce primary hard CV composite in secondary-prevention moderate–severe OSA — do not oversell CV hard-endpoint prevention, but still treat for symptoms, BP, and mood/QoL rationale.[7]

(v) Monitoring. If SGAs ever required for mood/psychosis, monitor weight, glucose, lipids; re-screen OSA if BMI rises. Avoid restarting chronic benzodiazepines; if short-term sedation unavoidable, lowest dose with medical oversight and exit plan.[8][10]